力扑素联合奈达铂治疗卵巢癌的临床效果分析  

Clinical Analysis on Efficacy of Paclitaxel Liposome Combined with Nedaplatin for Ovarian Cancer Patients

作　　者：朱艳清[1] 王吉[1] 郭亮生[1] 吴菊英[1] 胡玲[1] ZHU Yanqing;WANG Ji;GUO Liangsheng;WU Juying;HU Ling(Department of gynaecology, the second affiliated hospital of soochow university, Suzhou Jiangsu, 215000, China)

机构地区：[1]苏州大学附属第二医院妇科,江苏苏州215000

出　　处：《肿瘤药学》2019年第2期267-269,274,共4页Anti-Tumor Pharmacy

基　　金：苏州科教兴卫青年项目(KJXW2017015)

摘　　要：目的探究卵巢癌患者应用力扑素联合奈达铂治疗的临床效果及对患者生活质量的影响。方法选取我院收治的卵巢癌患者120例。根据治疗方案的不同分为两组,各60例。对照组应用力扑素治疗,观察组应用力扑素联合奈达铂治疗。对比两组患者的临床疗效、生活质量(QOL)评分和不良反应发生率。结果观察组患者的临床疗效明显优于对照组(P<0.05);观察组患者QOL评分显著高于对照组(P<0.05);观察组患者不良反应发生率显著低于对照组(P<0.05)。结论采用力扑素联合奈达铂治疗卵巢癌患者的临床疗效较好,可有效改善患者的生活质量,减轻不良反应。Objective To investigate the clinical effects of paclitaxel liposome combined with nedaplatin on patients with ovarian cancer and its impact on patients’ quality of life. Methods A total of 120 patients with ovarian cancer admitted to our hospital were enrolled in this study. According to the different treatment options, they were divided into two groups, 60 cases in each group. The control group was treated with paclitaxel liposome, while the observation group was treated with paclitaxel liposome plus nedaplatin. The clinical efficacy, quality of life(QOL) score and incidence of adverse reactions were compared between the two groups. Results The clinical efficacy of the observation group was significantly better than that of the control group(P<0.05). The QOL score of the observation group was significantly higher than that of the control group(P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that of the control group(P<0.05). Conclusion The paclitaxel liposome combined with nedaplatin had good curative effect on patients with ovarian cancer. It could effectively improve the quality of life of patients and reduce adverse reactions.

关 键 词：卵巢癌 力扑素 奈达铂 临床疗效 生活质量 

分 类 号：R737.31[医药卫生—肿瘤]